Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherBehavioral Pharmacology

Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures:In Vitro and In Vivo Studies with Opioids and Cannabinoids

Dana E. Selley, Matthew L. Banks, Clare M Diester, Abdul M Jali, Luke P. Legakis, Edna J Santos and S. Stevens Negus
Journal of Pharmacology and Experimental Therapeutics December 22, 2020, JPET-AR-2020-000349; DOI: https://doi.org/10.1124/jpet.120.000349
Dana E. Selley
1Dept. of Pharmacology & Toxicology, Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dana E. Selley
Matthew L. Banks
2Pharmacology and Toxicology, Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew L. Banks
Clare M Diester
2Pharmacology and Toxicology, Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdul M Jali
2Pharmacology and Toxicology, Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke P. Legakis
3Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edna J Santos
2Pharmacology and Toxicology, Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Stevens Negus
4Deptartment of Pharmacology and Toxicology, Virginia Commonwealth University, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ssnegus@vcu.edu
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Pharmacodynamic efficacy of drugs to activate their receptors is a key determinant of drug effects, and intermediate-efficacy agonists are often useful clinically because they retain sufficient efficacy to produce therapeutically desirable effects while minimizing undesirable effects. Molecular mechanisms of efficacy are not well understood, so rational drug design to control efficacy is not yet possible; however, receptor theory predicts that fixed-proportion mixtures of an agonist and antagonist for a given receptor can be adjusted to precisely control net efficacy of the mixture in activating that receptor. Moreover, the agonist proportion required to produce different effects provides a quantitative scale for comparing efficacy requirements across those effects. To test this hypothesis, the present study evaluated effectiveness of fixed-proportion agonist/antagonist mixtures to produce in vitro and in vivo effects mediated by mu opioid receptors (MOR) and cannabinoid type-1 receptors (CB1R). Mixtures of the MOR agonist fentanyl and antagonist naltrexone, and of the CB1R agonist CP55,940 and antagonist/inverse agonist rimonabant, were evaluated in an in vitro assay of ligand-stimulated [35S]GTPgS binding and an in vivo assay of thermal nociception in mice. For both agonist/antagonist pairs in both assays, increasing agonist proportions produced graded increases in maximal mixture effects, and lower agonist proportions were sufficient to produce in vivo than in vitro effects. These findings support the utility of agonist/antagonist mixtures as a strategy to control net efficacy of receptor activation and to quantify and compare efficacy requirements across a range of in vitro and in vivo endpoints.

Significance Statement Significance Statement: Manipulation of agonist proportion in agonist/antagonist mixtures governs net mixture efficacy at the target receptor. Parameters of agonist/antagonist mixture effects can provides a quantitative metric for comparison of efficacy requirements across a wide range of conditions.

  • antinociception
  • cannabinoid receptors
  • drug efficacy
  • Drug interactions
  • G proteins (GTP-binding proteins)
  • opioid receptors
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 2
1 Feb 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures:In Vitro and In Vivo Studies with Opioids and Cannabinoids
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherBehavioral Pharmacology

Manipulating efficacy with agonist/antagonist mixtures

Dana E. Selley, Matthew L. Banks, Clare M Diester, Abdul M Jali, Luke P. Legakis, Edna J Santos and S. Stevens Negus
Journal of Pharmacology and Experimental Therapeutics December 22, 2020, JPET-AR-2020-000349; DOI: https://doi.org/10.1124/jpet.120.000349

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherBehavioral Pharmacology

Manipulating efficacy with agonist/antagonist mixtures

Dana E. Selley, Matthew L. Banks, Clare M Diester, Abdul M Jali, Luke P. Legakis, Edna J Santos and S. Stevens Negus
Journal of Pharmacology and Experimental Therapeutics December 22, 2020, JPET-AR-2020-000349; DOI: https://doi.org/10.1124/jpet.120.000349
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Concentration-response analysis human taste discrimination
  • Varenicline and epibatidine as opioid adjuvants
  • MCAM reverses and prevents fentanyl ventilatory depression
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics